SPDR Advertisement SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Genetic Testing for Cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hlegweakreturns Member Profile
Followed By 1
Posts 445
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
U.S. Congressman Patrick Meehan to Present Keynote Address at 22nd Annual Groundhog Investment Forum "Business Wire" - 2/3/2015 10:15:00 AM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 2/2/2015 4:40:20 PM
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences "GlobeNewswire Inc." - 2/2/2015 8:00:00 AM
Investment Industry to Gather in Philadelphia at 22nd Annual Groundhog Day Investment Forum "Business Wire" - 1/29/2015 12:05:00 PM
Inovio Pharmaceuticals Appoints Dr. Mark Gelder to Lead Clinical Development of Cervical Dysplasia and Cancer Programs "PR Newswire (US)" - 1/29/2015 8:00:00 AM
The Future of Cancer Science "InvestorsHub NewsWire" - 1/14/2015 9:00:00 AM
Inovio Pharmaceuticals' CEO to Present at 2015 Biotech Showcase Conference "PR Newswire (US)" - 1/7/2015 8:00:00 AM
Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV "PR Newswire (US)" - 1/6/2015 8:00:00 AM
Inovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers "PR Newswire (US)" - 12/18/2014 6:00:00 AM
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology "PR Newswire (US)" - 12/17/2014 8:00:00 AM
Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index "PR Newswire (US)" - 12/15/2014 8:00:00 AM
Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market "PR Newswire (US)" - 11/24/2014 6:00:00 AM
Inovio Pharmaceuticals Melanoma DNA Immunotherapy Inhibits Tumor Growth and Increases Survival in Preclinical Study "PR Newswire (US)" - 11/20/2014 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/17/2014 4:36:09 PM
Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreem... "PR Newswire (US)" - 11/17/2014 3:00:00 AM
Inovio to Present at Upcoming Investor Conferences "PR Newswire (US)" - 11/11/2014 6:00:00 AM
Inovio Pharmaceuticals Reports 2014 Third Quarter Financial Results "PR Newswire (US)" - 11/10/2014 6:00:00 AM
Inovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014 "PR Newswire (US)" - 11/4/2014 6:00:00 AM
Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bac... "PR Newswire (US)" - 10/21/2014 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/9/2014 4:15:45 PM
Inovio Pharmaceuticals Appoints Vice President of Commercial Development "PR Newswire (US)" - 9/30/2014 7:00:00 AM
Correction to Inovio, GeneOne Headline "Dow Jones News" - 9/24/2014 10:41:48 AM
U.S. Hot Stocks: Hot Stocks to Watch "Dow Jones News" - 9/24/2014 9:50:49 AM
Inovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science "PR Newswire (US)" - 9/24/2014 6:00:00 AM
Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers "PR Newswire (US)" - 9/22/2014 8:00:00 AM
hlegweakreturns   Friday, 10/18/13 06:04:49 AM
Re: None
Post # of 12793 
Genetic Testing for Cancer
Is evolving very quickly and many folks are getting into the business. And there is more than one in New Jersey. Roche is entering this market, and they are not alone. Yesterday Bloomberg had an article on Quest entering the Breast-Cancer Test Market that is currently dominated by Myriad. I don't think Roche has any interest in Quest, but they obviously are looking for expanding their genetic diagnostic capability going forward, as evidenced by the PACB deal, and another agreement with a smaller, and interesting player in this market. So here is the article if you have any interest in tangential developments:

"Quest Diagnostics Inc. (DGX), the biggest U.S. operator of medical labs, began yesterday to sell a test for two breast cancer genes, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.Quest will sell the most comprehensive version of its test for the BRCA1 and BRCA2 genes for $2,500, said Richard Bender, a consultant for the Madison, New Jersey-based company. The price compares with almost $3,400 that Medicare pays for the most comprehensive version of a test from Myriad.

Myriad held a U.S. monopoly over the BRCA tests until June, when the U.S. Supreme Court invalidated parts of its gene patents. Immediately afterward, Ambry Genetics Corp. and another closely held company said they were entering the BRCA market. Quest is the largest competitor to move into the field. Quest’s test “will certainly be comparable to if not better than the data provided by Myriad” in its ability to identify a harmful mutation, Bender said by telephone.
Quest’s incursion into the BRCA testing market sets up a potential legal battle with Myriad, which has various remaining patents on its tests. “We feel we offer a test that is the gold standard in quality,” Ronald Rogers, a Myriad spokesman, said in a phone interview." http://www.bloomberg.com/news/2013-10-16/interdigital-mattel-navistar-intellectual-property.html?cmpid=yhoo

Quest’s test “does not violate any valid BRCA patent that Myriad Genetics may assert,” Wendy Bost, a Quest spokeswoman, said in an e-mail.
Quest said in an Oct. 10 complaint filed in federal court in Santa Ana, California, that it believes Myriad will bring a patent-infringement lawsuit if it starts selling its BRCA test products.
Myriad hasn’t yet been served with Quest’s complaint, said Rogers. “Once we receive that, we will read through it and weigh our options,” he said.
The case is Quest Diagnostics Inc. v. Myriad Genetics Inc. (MYGN), 13-cv-01587, U.S. District Court, Central District of California (Santa Ana).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist